DETECTION AND ITS CLINICAL VALUE OF MINIMAL RESIDUAL DISEASES IN ACUTE PROMYELOCYTIC LEUKEMIA

• Published in: Chinese journal of cancer research Vol. 14; no. 4; pp. 288 - 292
• Main Authors: Jiang, Guo-sheng, Tang, Tian-hua, Bi, Ke-hong, Zhang, Yu-kun, Ren, Hai-quan, Zhao, Liang-yu, Guo, Gui-yue, Liu, Xiu-lan, Ren, Qing-hua, Jiang, Feng-qin, Liu, Chuan-fang, Peng, Jun, Tian, Zhi-gang
• Format: Journal Article
• Language: English
• Published: Department of Hemato-oncology, Shandong Academy of Medical Sciences, Shandong University, Jinan 250062%Department of Hematology, Shandong Qian-Fe-Shan Hospital, Jinan 250014%Department of Hematology, Shandong University Qilu Hospital, Jinan 250012 01.12.2002
• Subjects: APL; disease; Minimal; PCR; residual; Minimal residual disease; APL; PCR
• ISSN: 1000-9604; 1993-0631
• DOI: 10.1007/s11670-002-0063-y

Objective: To detect the minimal residual diseases (MRD) in acute promyelocytic leukemia (APL) after complete remission (CR) and to analyze its clinical value in prognosis. Methods: Reverse transcription Polymerase chain reaction (RT/PCR) was used to detect MRD of patients with APL. Results: MRD positive rate in patients with APL was 92.8% (39/42) before treatment and 56.7 (21/37) immediately after the ATRA or chemotherapy- induced CR. Furthermore, MRD positive rate wasrelated to the relapse in APL patients and could be considered as a marker to predict the relapse of patients with APL after CR. The MRD detection could also be applied to direct the consolidation therapy to prevent relapses. Conclusion: RT-PCR is valuable to monitor MRD and can be used as a marker to predict relapses.